Stem Cell Therapy for Rotator Cuff Tears: The Tear-Size Ladder for 2026

Introduction: Why “Full-Thickness vs. Partial” Isn’t Precise Enough

Rotator cuff tears are among the most common shoulder problems, and they become more common with age. Population studies show that full-thickness tears affect roughly 20-22% of the general population. Prevalence rises from under 5% in people younger than 40 to more than 35% in those aged 80 and older. A 2026 meta-analysis pooled full-thickness tear prevalence at 21.0%. Many of these tears cause no symptoms, but the ones that do often send patients looking for alternatives to surgery.

That search usually leads to oversimplified answers. Most patient-facing content reduces candidacy to a yes-or-no question: partial tears are good candidates, and full-thickness tears need surgery. Some articles add an Ellman-grade timing window. Neither approach helps a patient whose MRI report describes a 2.5cm full-thickness tear and who wants to know whether cellular therapy can realistically help.

The missing layer of precision is the centimeter-based Cofield classification, which sorts full-thickness tears into small (<1cm), medium (1-3cm), large (3-5cm), and massive (>5cm). This article uses that scale to build a size-ladder decision tool based on exact tear dimensions.

The sections below cover:

• The evidence tier for each tear size
• The biological “scaffold” concept that determines whether cells have anything to work on
• Data on stem cells as a surgical adjunct
• The hard ceiling at the massive-tear tier
• The FDA regulatory context patients need for due diligence

The central point is simple. Outcomes for stem cell therapy in rotator cuff tears depend less on the label “partial vs. full” and more on how many centimeters of tendon damage exist and how much healthy tissue remains.

The Classification Systems Behind the Size Ladder

Clinicians use two different scales depending on the type of tear. When the two are conflated, patient-facing content becomes confusing.

The distinction affects candidacy because the scales measure different things. Partial tears are graded by depth and percentage of tendon thickness. Full-thickness tears are graded by absolute length. Each measurement corresponds to a different way that stem cells might, or might not, contribute to healing.

Ellman’s Classification: Grading Partial-Thickness Tears

Ellman’s system grades partial-thickness tears by how deep they extend into the tendon:

• Grade I: less than 3mm deep, involving up to 25% of tendon thickness
• Grade II: 3-6mm deep, involving 25-50% of tendon thickness
• Grade III: 6mm or deeper, involving more than 50% of tendon thickness

By definition, a partial tear leaves part of the tendon intact. That remaining structure is why this category is the strongest candidate for injection-only treatment, as the evidence section below shows.

Cofield’s Classification: Grading Full-Thickness Tears by Centimeter

Cofield’s system measures full-thickness tears by length:

Cofield Tier	Tear Length
Small	Less than 1cm
Medium	1-3cm
Large	3-5cm
Massive	Greater than 5cm

Competitor content often skips this classification, even though it largely determines whether cellular therapy has a biological chance of working on a full-thickness tear.

The massive tier deserves particular attention. Massive tears account for roughly 20% of all rotator cuff tears but about 80% of recurring tears (retears). That imbalance shows how much riskier this category is than the others.

The Scaffold Concept: Why Centimeters, Not Just “Full-Thickness,” Determine Candidacy

Stem cells and cell concentrates do not build new tendon out of nothing. They need residual fibers, a scaffold, that they can populate, multiply on, and help remodel.

According to the research literature, stem cells have three relevant properties:

• High proliferation: they multiply readily.
• Paracrine signaling: they release signals that influence surrounding cells.
• Differentiation potential: they can develop into other cell types.

Together, these properties promote tendon remodeling and fibrocartilage formation. Extracellular vesicles derived from stem cells may also increase collagen synthesis and reduce inflammation and adhesion formation. All of these effects require existing tissue architecture to act on.

Some clinics in the field state this limit openly: injections will not work on tears that have no scaffold or remaining fibers onto which new tissue can grow. That biological fact sets the ladder’s hard ceiling at the massive-tear tier.

The Tear-Size Ladder: Candidacy Tier by Tier

The ladder below is the core decision tool of this article. It moves step by step from the best-case candidacy to the worst-case, with the supporting evidence attached to each rung.

Rung 1: Partial-Thickness Tears (Ellman I-III), the Strongest Non-Surgical Evidence

Partial-thickness tears have the most robust support for injection-based cellular therapy.

• Randomized trial evidence: In a peer-reviewed registered trial comparing adipose-derived regenerative cells to corticosteroid injection, adipose-derived mesenchymal stem cells (MSCs) produced statistically significant improvements in both pain and function at 12 months compared with corticosteroid injection in partial-thickness tears.
• Long-term follow-up: A 4-year observational study of culture-expanded, bone-marrow-derived MSCs confirmed continued safety and efficacy for partial-thickness tears. Significant gains in pain and function appeared at every time point from 3 months to 2 years.

The comparison with corticosteroids is especially relevant. Subacromial steroid injection carries a risk of turning a partial-thickness tear into a full-thickness tear. A treatment meant to relieve pain could therefore move a patient further up the ladder, which strengthens the case for regenerative alternatives at this tier.

Verdict: This is the clearest “yes” on the ladder.

Rung 2: Small Full-Thickness Tears (<1cm), Scaffold Fully Intact

A small full-thickness tear goes through the tendon, but most of the surrounding tendon architecture remains intact. For injection purposes, these tears behave much like partial tears.

A randomized controlled trial compared injections of bone marrow aspirate concentrate (BMAC) and a platelet product with exercise therapy in partial and full-thickness supraspinatus tears. BMAC significantly improved function and pain at 3 months compared with exercise therapy alone.

Verdict: This tier generally supports trying injections first and reserving surgery for later if needed. Because the scaffold is preserved, injections can be attempted without closing off surgical options.

Rung 3: Medium Full-Thickness Tears (1-3cm), Still Within the Evidence Base, With Caveats

The BMAC data described above also covers tears in this range. However, the evidence here is emerging and of moderate strength. It is not a guarantee.

A 2026 pilot safety trial on full-thickness tears added useful data:

• Safety: No systemic or local adverse events were reported during 36 months of follow-up.
• Pain: Scores on the visual analog scale (VAS) improved to 3.6 from a baseline of 8.5.
• Function: Scores on the Western Ontario Rotator Cuff Index (WORC), where lower scores indicate less disability, improved to 34.17 from a baseline of 47.53.

These results are encouraging, but pilot trials are small and early-stage. Reviewers continue to describe the overall evidence as promising yet limited by variation between studies and by regulatory constraints.

Verdict: At this tier, a patient’s activity level and goals start to matter as much as the measurement itself. A sedentary 68-year-old and a competitive 45-year-old tennis player with the same 2cm tear may reasonably choose different paths. Factors beyond tear size, discussed in a later section, also begin to influence the decision.

Rung 4: Large Full-Thickness Tears (3-5cm), Where Stem Cells Shift from Standalone to Adjunct

This is the pivot point of the ladder. At this size, evidence for standalone injections becomes thin. The better-supported role for cellular therapy is as an adjunct to surgery rather than a replacement for it.

The key statistic comes from a cohort study by Kim and colleagues. Adding adipose-derived stem cells (ADSCs) to arthroscopic repair reduced the retear rate to 14.3%, compared with 28.5% in the control group, on MRI at 1-year follow-up. Retears were cut roughly in half.

In practical terms, the stem cells are not healing the tear without surgery. They are making the surgical repair more durable. That is a different value proposition from avoiding surgery, but it is still a meaningful one.

Research in this area is becoming more structured. One registered randomized trial of 130 patients is evaluating bone-marrow-derived MSC augmentation of arthroscopic repair, using the American Shoulder and Elbow Surgeons (ASES) score at one year as its outcome measure. Studies of this design are how the adjunct role will be confirmed or refined.

Rung 5: Massive Tears (>5cm), the Hard Biological Ceiling

Massive, retracted tears generally fall outside the scope of treatment with stem cells alone. In many cases there is no remaining scaffold for the cells to act on.

As noted earlier, massive tears represent about 20% of all rotator cuff tears but 80% of recurring tears. This is the highest-risk, most failure-prone category regardless of which treatment a patient chooses.

The clinical consensus is consistent. The following findings usually require surgery to physically reattach the tendon before any regenerative treatment can meaningfully help:

• Large tears, or tears with significant retraction
• Noticeable muscle atrophy
• A tendon that has pulled away from the bone

Verdict: This is the limit of the ladder. A clear “no” for injection-only treatment at this tier protects patients from spending time on an approach that is unlikely to help, and it allows regenerative therapy to be used where it fits best: alongside a surgical repair.

Two Factors Beyond Centimeters: Retraction and Fatty Infiltration

Tear length is not the only factor that matters. Two independent measures, rarely discussed in consumer content, can move a tear’s outlook up or down the ladder.

• Patte classification (retraction grade): This measures how far the torn tendon has pulled back toward the shoulder blade. Greater retraction means the tendon edge is farther from where it needs to heal.
• Goutallier stage (fatty infiltration): This grades how much of the rotator cuff muscle has been replaced by fat. Higher stages indicate muscle that is less able to recover function.

These factors explain why a tear’s measurement alone can be misleading. A 2cm tear with significant retraction or advanced fatty infiltration may behave biologically more like a large or massive tear, even though Cofield’s scale classifies it as medium. In the other direction, a well-preserved medium tear in healthy muscle may have a better outlook than its size suggests.

An accurate candidacy assessment therefore requires reviewing three things on imaging together: tear size, degree of retraction, and muscle quality.

Recovery Timelines by Path: What the Size Ladder Means for Daily Life

The rung a patient falls on largely determines which treatment path is realistic, and the two paths differ considerably in recovery time.

Milestone	Injection-Based Path	Surgical Repair Path
Light activity	Within a few days	Delayed; follows rehabilitation protocol
Normal movement	Four to six weeks	Typically 4-6 months of rehabilitation
Continued healing or full strength	Two to three months	An additional 6-12 months

Even a successful surgical repair does not guarantee a full return to previous activity. In one study of 725 eligible patients, only 57.4% achieved full return to sport at 24 months, and 43.8% returned to their primary pre-injury sport. Patients at the large and massive tiers should factor this into their expectations.

More intervention also does not automatically produce better results. An analysis of eleven high-level studies found that surgery was no better than physical therapy at restoring function in some groups of patients. The aim is to match the treatment to the biology of the tear, not to choose the most aggressive option by default.

Closing the Trust Gap: FDA Regulatory Status in 2026

Much of the content aimed at patients avoids this topic. As of 2026, no stem cell, PRP, or exosome product has FDA approval for any orthopedic condition. FDA consumer alerts specifically list shoulder pain, tendonitis, and osteoarthritis among the conditions for which no such product has been approved. Any clinic that markets an “FDA-approved” stem cell treatment for rotator cuff tears is misrepresenting the facts.

Understanding how these treatments are regulated starts with two categories under federal law:

• Section 361 procedures: These are minimally manipulated, autologous procedures, meaning they use the patient’s own tissue, and are often performed on the same day. They fall into a different regulatory category that does not require premarket approval when the applicable criteria are met.
• Section 351 products: These are more extensively manipulated cellular products, such as cells grown in a laboratory, and the FDA regulates them as biologic drugs. They require FDA approval, and no such approval exists yet for any orthopedic indication.

2026 Enforcement Context: Why This Isn’t Theoretical

Regulatory enforcement in this area is active. In August 2026, the FDA sent a warning letter to R3 Medical Companies, a business based in Scottsdale, Arizona, over unapproved exosome products sold under the names ReBellaXO and ReBellaXOL.

Patients should also watch for a specific fraud pattern. Some clinics market umbilical cord or “birth tissue” stem cells for rotator cuff tears, but several studies have shown that these products frequently contain no viable stem cells. Patients in these cases pay for a stem cell treatment and receive something else.

Before treatment, patients should ask any clinic three direct questions:

1. Cell source: Do the cells come from the patient’s own bone marrow or fat, or from donor or birth tissue?
2. Manipulation level: Are the cells minimally manipulated and processed on the same day, or are they cultured and expanded in a laboratory?
3. Regulatory category: Is the treatment offered as a Section 361 procedure or a Section 351 product, and what is its legal basis?

A reputable provider should be able to answer all three clearly.

How This Size-Ladder Framework Shapes Care at Unicorn Bioscience

Unicorn Bioscience offers several treatment options, including BMAC, adipose-derived cells, PRP, and exosome therapy. Different tear sizes call for different tools, so a single standard injection would not suit every patient.

Assessment relies on imaging guidance with ultrasound and X-ray. Imaging is used to establish the exact Ellman or Cofield grade, along with retraction and fatty infiltration, before any treatment path is recommended. The same technology guides the injections themselves so that therapeutic material reaches the intended tissue.

Treatment planning is personalized. It accounts for injury size and location, inflammation levels, age, current medications, and the patient’s goals. This is the practical application of the ladder described throughout this article.

Transparency is a core part of the practice’s approach. Unicorn Bioscience openly states that no orthopedic stem cell, PRP, or exosome product is FDA-approved in 2026. For massive or retracted tears, an honest assessment means referring patients for surgical evaluation rather than overselling injections.

Patients can begin with a virtual or in-person consultation at any of the practice’s eight locations to receive a candidacy assessment specific to their tear size.

Conclusion: Let Tear Size, Not Binary Labels, Guide the Decision

A “full-thickness” diagnosis is not a final verdict on treatment options. The exact measurement in centimeters, the degree of retraction, and the quality of the surrounding tissue determine whether cellular therapy has the biological room to work.

The ladder summarizes the evidence:

• Partial and small tears have the strongest evidence for injection-only treatment.
• Medium tears have emerging evidence that is promising but not yet definitive.
• Large tears shift stem cells into a surgical-adjunct role, where they measurably reduce retear rates.
• Massive tears generally require surgery first because little or no scaffold remains.

Decisions based on specific tear measurements and current evidence, combined with clear information about regulatory status, distinguish genuine due diligence from marketing claims. The most useful next step is to obtain an exact, imaging-based measurement of the tear rather than relying on a general diagnostic label.

Get a Precise, Size-Based Candidacy Assessment

Patients who already have an MRI or ultrasound diagnosis can schedule a virtual or in-person consultation with Unicorn Bioscience. The consultation determines the exact Cofield or Ellman grade and identifies realistic treatment options.

Qualified candidates may be able to receive same-day treatment, drawing on BMAC, adipose-derived cells, PRP, or exosomes as appropriate to the size of the tear.

Patients can call (737) 347-0446 to schedule. Unicorn Bioscience has eight locations: Austin, Dallas, El Paso, Fort Worth, Houston, and San Antonio in Texas; Boca Raton in Florida; and Manhattan in New York. Virtual consultations are available for patients outside these areas.

Patients should bring their imaging, ask about cell source and regulatory category, and get an answer specific to their tear size before deciding between injection, surgery, or a combined approach.